Alcon AG vs 8x8 Inc — how do they compare? Alcon AG trades at $75 (market cap $35.19B), while 8x8 Inc trades at $2.16 (market cap $323.54M). The key difference: Alcon AG is far larger — about 108.8× 8x8 Inc's market cap, and Alcon AG pays a 0.49% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals.
| ALC | EGHT | |
|---|---|---|
Market Cap | $35.19B | $323.54M |
Sector | Health | Technology |
52-Week High | $90.12 | $2.76 |
52-Week Low | $62.02 | $1.59 |
Enterprise Value | $39.03B | $590.46M |
Dividend Yield | 0.49% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $71.81, up 3.26% today, with a bullish technical signal supported by moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.84, beating estimates, and raised its profit guidance on August 11, 2026, citing strong product launches. Revenue grew to $10.4B in 2025, though net income margin dipped to 9.42%. Valuation ratios include a P/E of 43 and P/S of 3.34, reflecting premium pricing.
Outlook is positive with analyst consensus at 54% buy ratings and a 27.8% upside target, but risks include margin pressure and high debt. The stock offers growth potential from innovation but faces competitive and macroeconomic headwinds.
EGHT trades at $2.30, up 1.1% today, with a bullish technical signal from moving averages. The company shows strong revenue growth, with five consecutive quarters of year-over-year increases, and has beaten EPS estimates in recent quarters. Recent news highlights the launch of a new partner program and expansion of AI capabilities across its platform. However, the stock carries a high P/E ratio of 74.67, and the company reported a net loss of $27.21 million for 2025.
The outlook is cautiously optimistic, with analyst consensus pointing to significant upside with a $3.13 price target. Key opportunities include sustained revenue growth and AI-driven product expansion, while risks involve high valuation, debt levels, and the challenge of achieving consistent profitability. Institutional sentiment is mixed but leans positive.
Trailing returns across standard periods
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →